Novartis Pharmaceuticals Canada Inc. Sustainability Profile
Novartis Pharmaceuticals Canada Inc., a subsidiary of the global healthcare leader Novartis AG, is headquartered in Canada and operates extensively across the country. Founded in 1996, the company has established itself as a key player in the pharmaceutical industry, focusing on innovative medicines and advanced therapies in areas such as oncology, cardiology, and immunology. With a commitment to research and development, Novartis Canada has introduced several groundbreaking treatments that address unmet medical needs, setting them apart in a competitive market. Their portfolio includes unique biologics and targeted therapies that have significantly improved patient outcomes. Recognised for its contributions to healthcare, Novartis holds a strong market position, consistently ranking among the top pharmaceutical companies in Canada.
DitchCarbon Score
How does Novartis Pharmaceuticals Canada Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Pharmaceuticals Canada Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis Pharmaceuticals Canada Inc. currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. However, the company is part of a broader corporate family that includes Novartis AG, which has established significant climate commitments and initiatives. As a current subsidiary of Novartis AG, Novartis Pharmaceuticals Canada Inc. inherits various sustainability targets and initiatives from its parent company. Novartis AG has set ambitious science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These targets encompass Scope 1, 2, and 3 emissions, reflecting a comprehensive approach to climate action. While specific reduction targets for Novartis Pharmaceuticals Canada Inc. are not detailed, the overarching commitments from Novartis AG include participation in initiatives such as the Carbon Disclosure Project (CDP), RE100, and the Race to Zero campaign. These initiatives underscore the company's dedication to achieving net-zero emissions and enhancing sustainability practices across its global operations. In summary, while Novartis Pharmaceuticals Canada Inc. does not report specific emissions data, it aligns with the climate commitments and reduction initiatives set forth by Novartis AG, demonstrating a commitment to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Novartis Pharmaceuticals Canada Inc.'s Industry?
How Carbon Intensive is Novartis Pharmaceuticals Canada Inc.'s Location?
Novartis Pharmaceuticals Canada Inc.'s Scope 3 Categories Breakdown
Novartis Pharmaceuticals Canada Inc.'s Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Novartis Pharmaceuticals Canada Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Pharmaceuticals Canada Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.